Skip to main content

Advertisement

SpringerLink
Log in

Safety of intravitreal metoprolol in eyes with central serous chorioretinopathy

  • Original Research Article
  • Published:
Documenta Ophthalmologica Aims and scope Submit manuscript

Abstract

Purpose

To investigate ocular safety of intravitreal metoprolol in eyes with central serous chorioretinopathy.

Methods

Five eyes of five patients diagnosed with chronic central serous chorioretinopathy (cCSC) previously treated unsuccessfully with oral spironolactone, micropulse laser and intravitreal anti‐vascular endothelial growth factor agents were enrolled and received off-label intravitreal metoprolol (50 µg/0.05 ml). Baseline and follow-up examinations included measurement of best-corrected visual acuity (BCVA), intraocular pressure, anterior chamber cellular/flare scores, vitritis classification, fluorescein and indocyanine green angiography, spectral domain optical coherence tomography and electroretinography (ERG), recorded by means of DTL electrodes and following the standard suggested by the International Society for Clinical Electrophysiology of Vision (ISCEV). The total follow-up period was 4 weeks.

Results

There were no significant differences between baseline and follow-up ERG parameters: scotopic or photopic, a- and b-wave amplitude and implicit time, nor oscillatory potentials amplitude, or whatsoever. No intraocular inflammation sign was observed. In addition, BCVA showed small improvement in 4 or kept baseline values in 1 patient. The subretinal and/or intraretinal fluid volume reduced in all patients at 1 month after treatment.

Conclusion

Patients with refractory cCSC treated with intravitreal 50 µg/0.05 ml metoprolol showed no signs of acute ocular toxicity, along with intraretinal fluid reduction and slight BCVA improvement 1 month after injection. This data suggest that intravitreal metoprolol may be a safe alternative for cCSC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Stefánsson E, Geirsdóttir A, Sigurdsson H (2011) Metabolic physiology in age related macular degeneration. Prog Retin Eye Res 30(1):72–80

    Article  PubMed  Google Scholar 

  2. Tatham A, Macfarlane A (2006) The use of propranolol to treat central serous chorioretinopathy: an evaluation by serial OCT. J Ocul Pharmacol Ther 22(2):145–149

    Article  CAS  PubMed  Google Scholar 

  3. Kianersi F, Farnaz F (2008) Effects of propranolol in patients with central serous chorioretinopathy. J Res Med Sci 13(3):103–107

    CAS  Google Scholar 

  4. Chen LC, Ma JW, Shieh PC, Horng CT (2020) Oral treatment of central serous chorioretinopathy patients using propranolol tablets. Pharmaceuticals (Basel) 13(11):336

    Article  CAS  Google Scholar 

  5. de Paiva MRB, Arribada RG, da Silva CN et al (2021) Assessment of the safety of intravitreal injection of metoprolol tartrate in rabbits. Doc Ophthalmol 142(1):75–85

    Article  PubMed  Google Scholar 

  6. Chaves L, Messias A, Correa Z, Jorge R (2021) Intravitreal metoprolol for circumscribed choroidal hemangiomas: a phase I clinical trial. Graefes Arch Clin Exp Ophthalmol. https://doi.org/10.1007/s00417-021-05153-9

    Article  PubMed  Google Scholar 

  7. Robson AG, Frishman LJ, Grigg J, Hamilton R, Jeffrey BG, Kondo M, Li S, McCulloch DL (2022) ISCEV Standard for full-field clinical electroretinography (2022 update). Doc Ophthalmol 144(3):165–177

    Article  PubMed  PubMed Central  Google Scholar 

  8. Mrejen S, Balaratnasingam C, Kaden TR, Bottini A, Dansingani K, Bhavsar KV, Yannuzzi NA, Patel S, Chen KC, Yu S, Stoffels G, Spaide RF, Freund KB, Yannuzzi LA (2019) Long-term visual outcomes and causes of vision loss in chronic central serous chorioretinopathy. Ophthalmology 126(4):576–588

    Article  PubMed  Google Scholar 

  9. van Rijssen TJ, van Dijk EHC, Yzer S et al (2019) Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Prog Retin Eye Res 73:100770

    Article  PubMed  Google Scholar 

  10. Khosla PK, Rana SS, Tewari HK, Azad RU, Talwar D (1997) Evaluation of visual function following argon laser photocoagulation in central serous retinopathy. Ophthalmic Surg Lasers 28:693–697

    Article  CAS  PubMed  Google Scholar 

  11. Scholz P, Altay L, Fauser S (2017) A review of subthreshold micropulse laser for treatment of macular disorders. Adv Ther 34(7):1528–1555

    Article  PubMed  PubMed Central  Google Scholar 

  12. van Rijssen TJ, van Dijk EHC, Scholz P et al (2019) Focal and diffuse chronic central serous chorioretinopathy treated with half-dose photodynamic therapy or subthreshold micropulse laser: place trial Report No. 3. Am J Ophthalmol 205:1–10

    Article  PubMed  Google Scholar 

  13. Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB (2019) Pachychoroid disease. Eye (Lond) 33:18–33

    Article  Google Scholar 

  14. Erikitola OC, Crosby-Nwaobi R, Lotery AJ et al (2014) Photodynamic therapy for central serous chorioretinopathy. Eye 28:944–957

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Roca JA, Wu L, Fromow-Guerra J, Rodriguez FJ, Berrocal MH, Rojas S et al (2018) Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American colla- borative retina study (pacores) group. Br J Ophthalmol 102:1696–1700

    Article  PubMed  Google Scholar 

  16. Sun J, Tan J, Wang Z, Yang H, Zhu X, Li L (2003) Effect of catecholamine on central serous chorioretinopathy. J Huazhong Univ Sci Technol Med Sci 23(3):313–316

    Article  CAS  Google Scholar 

  17. Yannuzzi LA (1987) Type-A behavior and central serous chorioretinopathy. Retina Summer 7(2):111–31

    Article  CAS  Google Scholar 

  18. Yoshioka H, Katsume Y (1982) Experimental central serous chorioretinopathy. III: ultrastructural findings. Jpn J Ophthalmol 26(4):397–409

    CAS  PubMed  Google Scholar 

  19. Miki T, Sunada I, Higaki T (1972) Studies on chorioretinitis induced in rabbits by stress (repeated administration of epinephrine). Nippon Ganka Gakkai Zasshi 76(9):1037–1045

    CAS  PubMed  Google Scholar 

  20. Sibayan SA, Kobuch K, Spiegel D et al (2000) Epinephrine, but not dexamethasone, induces apoptosis in retinal pigment epithelium cells in vitro: possible implications on the pathogenesis of central serous chorioretinopathy. Graef Arch Clin Exp Ophthalmol 238(6):515–519

    Article  CAS  Google Scholar 

  21. Frambach DA, Fain GL, Farber DB, Bok D (1990) Beta adrenergic receptors on cultured human retinal pigment epithelium. Invest Ophthalmol Vis Sci 31(9):1767–1772

    CAS  PubMed  Google Scholar 

  22. Cheong HI, Johnson J, Cormier M, Hosseini K (2008) In vitro cytotoxicity of eight beta-blockers in human corneal epithelial and retinal pigment epithelial cell lines: comparison with epidermal keratinocytes and dermal fibroblasts. Toxicol Vitro 22:1070–1076

    Article  CAS  Google Scholar 

  23. Jorge R, Chaves L, Cunha ADS, Correa ZM (2019) Alternative management of circumscribed choroidal hemangioma using intravitreal metoprolol. Retin Cases Brief Rep. https://doi.org/10.1097/ICB.0000000000000917

    Article  Google Scholar 

Download references

Funding

FAPESP and CNPq provided financial support in the form of research grants for Rodrigo Jorge and André Messias. The sponsors had no role in the design or conduct of this research.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Ribeirão Preto School of Medicine, University of São Paulo, 3900, Bandeirantes Avenue, Ribeirão Preto, SP,, 14049-900, Brazil

    Annelise Nicotti Gonçalves, André Messias, Leandro Chaves, Thaís Marino de Azeredo Bastos & Rodrigo Jorge

Authors
  1. Annelise Nicotti Gonçalves
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. André Messias
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leandro Chaves
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thaís Marino de Azeredo Bastos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rodrigo Jorge
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to André Messias.

Ethics declarations

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the local institutional research committee, (IRB approval number 4.580.295) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Statement of human rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the local and National Institutional Review Board (IRB approval number 4.580.295), and with the 1964 Helsinki Declaration and its later amendments.

Statement on the welfare of animals

This article does not contain any studies with animals performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gonçalves, A.N., Messias, A., Chaves, L. et al. Safety of intravitreal metoprolol in eyes with central serous chorioretinopathy. Doc Ophthalmol 145, 211–219 (2022). https://doi.org/10.1007/s10633-022-09895-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10633-022-09895-7

Keywords

Search

Navigation